

#11c 11/24/02 TBrag

S/N 09/524,454

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Kristian Berg et al.

Serial No.: 09/524,454

Filed: March 10, 2000

Title: METHOD OF VACCINATION

Examiner: Gerald Ewoldt

Group Art Unit: 1644

Docket: 697.013US1



RECEIVED  
JAN 07 2002  
TECH CENTER 1600/2900

**AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed on April 24, 2001. Please amend the above-identified patent application as follows.

This response is accompanied by a Petition, as well as the appropriate fee, to obtain a three-month extension of the period for responding to the Office action, thereby moving the deadline for response from July 24, 2001 to October 24, 2001.

**IN THE SPECIFICATION**

Please enter the enclosed SEQUENCE LISTING into the specification.

Please make the paragraph substitutions indicated in the appendix entitled Clean Version of Amended Specification Paragraphs. The specific changes incorporated in the substitute paragraphs are shown in the following marked-up versions of the original paragraphs:

On page 16, please replace the paragraph at lines 27-34 with the following:

C<sup>1</sup>  
Figure 4 shows the ability of PCI to deliver HRP into the cytosol. NHIK 3025 cells were treated with 3.2 ug/ml TPPS<sub>2A</sub> and 1mg/ml HRP for 18 hours. The medium was then replaced with drug-free medium before exposure to the indicated light doses. HRP activity was measured [in intact cells (°) and in cytosol (•)] in intact cells (•) and in cytosol (°) separated from cytosol-free cell corpses (•) by electroporomeabilisation and a density centrifugation technique.